RAG launches lupus patient support group in Ahmedabad

The initiative by Rheumatology Association of Gujarat is aimed at strengthening patient-centric autoimmune care

Dr. Reddy’s launches generic semaglutide in Canada

Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada

Lupin receives USFDA nod for Famotidine injection

Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market

Alembic Pharma receives USFDA tentative approval for Darolutamide tablets

Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States

Imfinzi-based regimens deliver major survival gains in muscle-invasive bladder cancer

The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents

Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation

The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies

Merck to showcase 100+ oncology studies at 2026 ASCO meeting

Highlighting KEYTRUDA & expanding cancer pipeline

Edwards Lifesciences highlights 10-year data reinforcing durability of RESILIA tissue

Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth

The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion

Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy